TK-8001

N/A

Report date: 2023/12/29 20:04:37

Base Information

Drug NameTK-8001

Drug Alias NameAntiMAGEA1 Tcell therapy TknifeTK8001T1367

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsMelanoma-associated antigen 1 modulators

TargetsMelanoma-associated antigen 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumNetherlandsGermany +[5]

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesT-knife Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesT-knife Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A